Acerus Pharmaceuticals Corp (ASP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012241
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation, is a pharmaceutical company that develops, manufactures, markets and distributes innovative branded products. It focuses on men’s and women’s health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Acerus’s product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corp (ASP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Partnerships 15
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Licensing Agreements 16
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 16
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 17
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 18
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 19
Hyundai Pharma Enters into Licensing Agreement with Acerus Pharma 20
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 21
Acerus Pharma Enters into Licensing Agreement with Medinova 22
Equity Offering 23
Acerus Pharma Raises USD2 Million in Private Placement of Shares 23
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 24
Trimel Pharma Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$45 Million 25
Trimel Pharma Announces Rights Offering Of Shares 27
Trimel Pharma Completes Public Offering Of Units For US$13 Million 28
Trimel BioPharma Completes Private Placement Of Units For US$30 Million 30
Debt Offering 31
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 31
Acquisition 32
J5 Acquisition And J5 (Barbados) Complete Acquisition Of Trimel BioPharma 32
Acerus Pharmaceuticals Corp – Key Competitors 33
Acerus Pharmaceuticals Corp – Key Employees 34
Acerus Pharmaceuticals Corp – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 07, 2017: Acerus Reports Third Quarter 2017 Financial Results 36
Aug 11, 2017: Acerus Reports Second Quarter 2017 Financial Results 38
Mar 08, 2017: Acerus Reports Fourth Quarter and Full Year 2016 Financial Results 40
Nov 02, 2016: Acerus Reports Third Quarter 2016 Financial Results 42
Aug 09, 2016: Acerus Reports Second Quarter 2016 Results 44
May 04, 2016: Acerus Reports First Quarter 2016 Results and Provides Business Update 46
Mar 02, 2016: Acerus Reports Fourth Quarter and Full Year 2015 Financial Results 48
Corporate Communications 50
Dec 07, 2017: Acerus Appoints Mr. Mark Lievonen to its Board of Directors 50
Oct 02, 2017: Acerus Announces Executive Leadership Change 51
May 05, 2017: Acerus Announces Appointment of Ken Yoon as Chief Financial Officer 52
Nov 01, 2016: Acerus Announces Appointment of Tricia Symmes as Chief Operating Officer 53
Jul 21, 2016: Acerus Appoints Mr. Luc Mainville to Its Board of Directors 54
Mar 24, 2016: Acerus Announces Departure of Dr. Michael Bumby 55
Legal and Regulatory 56
May 17, 2016: Acerus Provides Update on Litigation 56
Apr 08, 2016: Acerus comments on statement of claim 57
Apr 05, 2016: Litigation Against Acerus Pharmaceuticals Continues 58
Mar 09, 2016: Eugene Melnyk Initiates Legal Proceedings Against Acerus Pharmaceuticals, its Chairman, Ihor Ihnatowycz, and Others 59
Other Significant Developments 60
Dec 21, 2016: Acerus Comments on Decision Regarding Litigation 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 16
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 17
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 18
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 19
Hyundai Pharma Enters into Licensing Agreement with Acerus Pharma 20
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 21
Acerus Pharma Enters into Licensing Agreement with Medinova 22
Acerus Pharma Raises USD2 Million in Private Placement of Shares 23
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 24
Trimel Pharma Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$45 Million 25
Trimel Pharma Announces Rights Offering Of Shares 27
Trimel Pharma Completes Public Offering Of Units For US$13 Million 28
Trimel BioPharma Completes Private Placement Of Units For US$30 Million 30
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 31
J5 Acquisition And J5 (Barbados) Complete Acquisition Of Trimel BioPharma 32
Acerus Pharmaceuticals Corp, Key Competitors 33
Acerus Pharmaceuticals Corp, Key Employees 34
Acerus Pharmaceuticals Corp, Subsidiaries 35

★海外企業調査レポート[Acerus Pharmaceuticals Corp (ASP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Clarion Co Ltd:企業の戦略的SWOT分析
    Clarion Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Lario Oil & Gas Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Lario Oil & Gas Co (Lario Oil & Gas) is an oil and gas exploration and production company that explores and produces oil and gas properties. The company offers services such as discovering reserves organically from geologic thesis, drill-bit, field delineation, and land acquisition and explo …
  • Echo Therapeutics Inc (ECTE)-医療機器分野:企業M&A・提携分析
    Summary Echo Therapeutics Inc (Echo Therapeutics) is a medical device and a specialty pharmaceutical company, which develops wireless continuous glucose monitoring (CGM) system. Its product portfolio includes Continuous Glucose Monitoring, which is a CGM System, a skin preparation device, transderma …
  • Northbridge Financial Corporation:企業の戦略的SWOT分析
    Northbridge Financial Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Oxiteno SA Industria E Comercio:企業の戦略的SWOT分析
    Oxiteno SA Industria E Comercio - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Polyplex (Thailand) Public Company Limited:企業の戦略・SWOT・財務情報
    Polyplex (Thailand) Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Polyplex (Thailand) Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ashtead Group Plc (AHT):企業の財務・戦略的SWOT分析
    Ashtead Group Plc (AHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Evergreen Packaging Llc:企業の戦略・SWOT・財務分析
    Evergreen Packaging Llc - Strategy, SWOT and Corporate Finance Report Summary Evergreen Packaging Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Toshiba Plant Systems & Services Corporation (1983):企業の財務・戦略的SWOT分析
    Toshiba Plant Systems & Services Corporation (1983) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s ke …
  • HOCHTIEF AG:戦略・SWOT・企業財務分析
    HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report Summary HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Fountain Biopharma Inc (4159):製薬・医療:M&Aディール及び事業提携情報
    Summary Fountain Biopharma Inc (Fountain Biopharma), a subsidiary of Microbio Co Ltd, is a developer of therapeutic monoclonal antibodies and DNA aptamers. The company’s technologies include IgE development platform, IEA’s drug development platform and tumor stem cell culture platform. Its IgE devel …
  • Jura Energy Corp (JEC):企業の財務・戦略的SWOT分析
    Jura Energy Corp (JEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Flex Ltd (FLEX)-医療機器分野:企業M&A・提携分析
    Summary Flex Ltd (Flex), formerly Flextronics International Ltd, is a provider of technology solutions. It designs, manufactures and provides supply chain services to original equipment manufacturers. The company’s major solutions include disposables, drug delivery, diagnostics devices, automotive e …
  • Laboratory Corp of America Holdings (LH):医療機器:M&Aディール及び事業提携情報
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Choppies Enterprises Limited (CHOPPIES):企業の財務・戦略的SWOT分析
    Choppies Enterprises Limited (CHOPPIES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Arup Group Ltd:企業の戦略的SWOT分析
    Arup Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Scb Life Assurance Public Company Limited:企業の戦略・SWOT・財務分析
    Scb Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Scb Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Varex Imaging Corp (VREX):企業の財務・戦略的SWOT分析
    Varex Imaging Corp (VREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆